Navigation Links
OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Date:2/4/2009

nt with FDA on the design of a second Phase 3 registration trial featuring pain palliation via the SPA process. OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

OncoGenex holds an exclusive license for patents related to clusterin inhibition obtained from the University of British Columbia based on discoveries made by researchers at the Prostate Centre at Vancouver General Hospital. OGX-011 utilizes second generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of clusterin protein in tumor cells. OncoGenex and Isis partnered in the successful discovery and initial development of OGX-011 and, in 2008, amended their agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development costs and partnering decisions, subject to financial obligations to Isis.

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed enrollment in a Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.oncogenex.com.

'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... May 20, 2013 Cempra, Inc. (Nasdaq: ... differentiated antibiotics to meet critical medical needs in ... it presented data at the American Thoracic Society ... demonstrating the antibacterial and enhanced immunomodulatory ... Phase 2 clinical trial in outpatients with community ...
(Date:5/20/2013)... May 20, 2013 Researchers from the ... connection between lower back pain, and the acne causing P.acnes ... the system the bacteria seek out oxygen deprived location to ... the spinal column, P.acnes has the ability to live in ... Fernando Perez, a spokesman for “ The best acne treatment ...
(Date:5/20/2013)... May 20, 2013 In Early 2013, ... field of biotoxin related illnesses , announced his vision ... able to advance his protocol for treating Chronic Inflammatory ... the third physician to achieve certification in the Shoemaker ... able to practice the Shoemaker Protocol in other parts ...
(Date:5/17/2013)... Topricin Pain Relief and Healing Cream, ... among nationally recommended over-the-counter (OTC) health products 2012 ... News" Health in collaboration with "Pharmacy Times." ... Pharmacists Recommended designation” in the “Topical Analgesics” category, ... is the only homeopathic formula to earn that ...
Breaking Biology Technology:Cempra Presents Post-Phase 2 Analysis of Solithromycin's Efficacy and Safety Results from Patients with Community Acquired Bacterial Pneumonia (CABP) 2Adult Acne Treatment, Probiotic Action Shares New Insight How Treating Acne May Help Reduce Body Pain 2Dr. Ritchie Shoemaker Certifies Third Physician in His Treatment Protocol for Chronic Inflammatory Response Syndrome (CIRS) 2Pharmacists' Picks: Topical BioMedics' Topricin Listed on Top Recommended OTC Health Products 2
... Milestone triggers $10 million payment from Eli Lilly ... - BioMS Medical Corp. (TSX:,MS), a leading developer ... that the independent Drug Safety Monitoring Board (DSMB) ... analysis of efficacy,and safety and has recommended that ...
... Scotland, S.D. to start in Q4 ,08. , ... ... Coalition for Ethanol conference, http://www.poet.com [POET] announced that construction ... facility later this year. The pilot plant will be adjacent to ...
... ATSI ), manufacturer and marketer of state-of-the-art ... at the Fourth,Annual Noble Financial Equity Conference at ... Financial Officer of ATS Medical, will,present at 2:30 ... (Logo: http://www.newscom.com/cgi-bin/prnh/20040202/ATSILOGO ), Attendance at ...
Cached Biology Technology:BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 2BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 3BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis 4POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 2POET Announces That Cellulosic Ethanol Pilot Facility Will Be Operational This Year 3ATS Medical to Participate at the Fourth Annual Noble Financial Equity Conference 2
(Date:5/16/2013)... Access to Research Careers) Program has announced the ... Biology (SDB) 72nd Annual Meeting in Cancun, Mexico ... to promote the entry of students, postdoctorates and ... the basic science community and to encourage the ... Annual Meeting. , Awards are given to poster/platform ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
(Date:5/16/2013)... are about 23 million years old give unprecedented ... order, one of the most species-rich groups among ... paleontologist Professor Bettina Reichenbacher from the Division of ... and Environmental Sciences at Ludwig-Maximilians-Universitaet (LMU) in Munich ... fish fossils which they assign to the group ...
Breaking Biology News(10 mins):Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Testing people for heart disease might be just a ... created by a team of researchers from Harvard and Northeastern ... The FASEB Journal ( http://www.fasebj.org ), they describe ... cells needed to build vascular tissue, called endothelial progenitor cells, ...
... Boston, MA June 1, 2009 REGiMMUNE Corporation ... combination with a low-dose of Sirolimus, demonstrated enhanced efficacy ... and acute Graft-versus-Host disease (GvHD). This data is ... Induction by a Liposomal Formulation of KRN7000 (RGI-2001) Alone ...
... years modeled how different species are likely to respond ... populations within a species and the interactions between species, ... June issue of BioScience , by Eric Post ... these limitations can be avoided. Their approach, which relies ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2